Endo Pharmaceuticals Press Release (01/09/12)
Endo Pharmaceuticals has announced that, as a result of a temporary shut-down of Novartis Consumer Health's Lincoln, Neb., manufacturing facility, there will be a short-term supply constraint of Opana ER. The company also announced certain other Endo analgesic products manufactured at this facility may experience short-term supply disruptions. The suspension of production at the facility was done to facilitate Novartis' implementation of certain manufacturing process improvements. These improvements are intended to address the possibility of rare instances of errors in the packaging of the tablets, potentially resulting in product mix-ups.

Read the complete article